ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

venetoclax

Also written as “Venetoclax”, “ABT-199” and “ABT-199 (Main Cohort)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 3 companies.

Drug pageVenetoclax: every studyAll 486 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 22, 202167 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie5312 open or runningphase 4since Nov 22, 2021Apr 1, 2011Nov 2026phase 2 · NCT04895436
Hoffmann-La Rocheits history only131 open or runningphase 3since Dec 4, 2013Aug 10, 2012none ahead
Oncotherapeuticsits history only11 open or runningphase 2since Aug 11, 2023Aug 11, 2023none ahead

Also a collaborator on its studies: Johnson & Johnson, Baili-Bio (Chengdu) Pharmaceutical, Roche-Genentech, Merck, Sumitomo Pharma and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 38 studies since Apr 1, 2011.

  1. Sep 23, 2019Phase 3 study in Leukemia, Myeloid, AcuteNCT04102020 · 112 enrolled · United States, Australia, Canada and more
  2. Nov 11, 2019Phase 3 study in Leukemia, Myeloid, AcuteNCT04161885 · 465 enrolled · United States, Australia, Brazil and more
  3. Feb 17, 20202 phase 1 studiesNCT04274933, NCT04274907
  4. May 22, 2020Phase 3 study in Myelodysplastic SyndromesNCT04401748 · 531 enrolled · United States, Australia, Austria and more
  5. Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellNCT04477486 · 13 enrolled · Japan
  6. Aug 10, 2020Phase 3 study in Leukemia, Myeloid, AcuteNCT04509622 · 14 enrolled · Japan
  7. Mar 19, 2021Phase 1 study in Renal InsufficiencyNCT04810598 · 12 enrolled · United States
  8. May 19, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04895436 · 75 planned · United States, Australia, Austria and more
  9. Nov 22, 2021Phase 4 study in Leukemia, Myeloid, AcuteNCT05144243 · 44 enrolled · China
  10. Jun 12, 2023Phase 1 study in Healthy VolunteersNCT05909553 · 15 enrolled · United States
  11. Oct 2, 2023Phase 1 study in Healthy VolunteersNCT06070948 · United States
  12. Dec 17, 2024Phase 1 study in Healthy VolunteerNCT06742086 · 72 enrolled · United States
  13. Jun 23, 2025Phase 4 study in Leukemia, Myeloid, AcuteNCT07044687 · 100 planned · India
  14. Jan 28, 2026Phase 2 study in Waldenstrom MacroglobulinemiaNCT07387471 · 14 enrolled · Japan

Ahead

  1. Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04895436
  2. Jun 2027Primary completion: phase 2 study in Multiple MyelomaNCT02899052
  3. Jul 2027Primary completion: phase 3 study in Myelodysplastic SyndromesNCT04401748
  4. Aug 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03844048

TargetBeta

BCL2 →read by rule
“Apoptosis regulator Bcl-2 inhibitor”ChEMBL 37, by rule

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
lacutoclaxruleLupeng Pharmaceuticalphase 24
surzetoclaxAbbViephase 23
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

All 53 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07387471Waldenstrom Macroglobulinemia · Japan2Active, not recruitingJul 202814
NCT07044687Leukemia, Myeloid, Acute · India4RecruitingNov 2027100
NCT06742086Healthy Volunteer · United States1CompletedOct 8, 202572
NCT06070948Healthy Volunteers · United States1WithdrawnJul 28, 20250
NCT05909553Healthy Volunteers · United States1CompletedSep 22, 202315
NCT05144243Leukemia, Myeloid, Acute · China4Active, not recruitingMar 202644
NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more2RecruitingNov 202675
NCT04810598Renal Insufficiency · United States1CompletedAug 16, 202212
NCT04509622Leukemia, Myeloid, Acute · Japan3CompletedApr 15, 202114
NCT04477486Lymphoma, Mantle-Cell · Japan2CompletedFeb 9, 202213
NCT04401748Myelodysplastic Syndromes · United States, Australia, Austria and more3Active, not recruitingJul 2027531
NCT04274933Breast Neoplasms · United States, Germany, Japan and more1TerminatedOct 8, 20204
NCT04274907Carcinoma, Non-Small-Cell Lung · United States1TerminatedFeb 2, 20212
NCT04161885Leukemia, Myeloid, Acute · United States, Australia, Brazil and more3TerminatedSep 23, 2025465
NCT04102020Leukemia, Myeloid, Acute · United States, Australia, Canada and more3CompletedSep 29, 2022112
NCT03873493Leukemia · United States, Australia, Austria and more2CompletedNov 4, 202114
NCT03844048Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingAug 2027165
NCT03785184Multiple Myeloma · United States, Australia, Canada and more2WithdrawnAug 22, 20190
NCT03567616Multiple Myeloma · United States, Spain, United Kingdom2TerminatedJun 18, 20208
NCT03557619Hematologic Neoplasms · United States, Australia1RecruitingMar 21, 202612
NCT03539744Multiple Myeloma · United States, Australia, Canada and more3Active, not recruitingAug 2026265
NCT03484520Neoplasms · United States, Australia, Spain1TerminatedDec 1, 202248
NCT03441555Leukemia, Myeloid, Acute · United States, Germany, United Kingdom1CompletedJan 25, 202136
NCT03406156Leukemia, Lymphocytic, Chronic, B-Cell · United States3CompletedOct 12, 2021120
NCT03314181Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingMay 2031156
NCT03236857Neoplasms · United States, Australia, Canada and more1CompletedApr 19, 2023143
NCT03181126Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Australia1CompletedNov 11, 202069
NCT03112174Lymphoma, Mantle-Cell · United States, Australia, Belgium and more3CompletedJun 26, 2024366
NCT03069352Leukemia, Myeloid, Acute · United States, Argentina, Australia and more3CompletedFeb 15, 2019211
NCT02993523Leukemia, Myeloid, Acute · United States, Australia, Austria and more3Active, not recruitingDec 1, 2021443
NCT02980731Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Bulgaria and more3CompletedDec 29, 2021210
NCT02966782Myelodysplastic Syndromes · United States, Australia, Germany1CompletedApr 5, 202370
NCT02966756Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, New Zealand and more2Active, not recruitingDec 203066
NCT02942290Myelodysplastic Syndromes · United States, Australia, Canada and more1CompletedApr 15, 2026134
NCT02910583Leukemia · United States, Australia, Italy and more2CompletedNov 12, 2020323
NCT02899052Multiple Myeloma · United States, Australia, Hungary and more2Active, not recruitingJun 2027120
NCT02756611Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Belgium and more3CompletedApr 10, 2019258
NCT02755597Multiple Myeloma · United States, Australia, Brazil and more3CompletedMar 15, 2021291
NCT02287233Leukemia, Myeloid, Acute · United States, Australia, Germany and more2CompletedAug 10, 202194
NCT02265731Lymphoma, Non-Hodgkin · Japan2CompletedMar 12, 202138
NCT02141282Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedDec 22, 2021127
NCT02095574Lymphoma, Non-Hodgkin1WithdrawnSep 20140
NCT01994837Leukemia, Myeloid, Acute2CompletedDec 201432
NCT01969695Lymphoma, Non-Hodgkin · United States1CompletedDec 16, 201911
NCT01969682Lymphoma, Non-Hodgkin · United States1WithdrawnMay 20140
NCT01969669Lymphoma, Non-Hodgkin · United States1CompletedSep 201412
NCT01889186Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more2CompletedOct 28, 2020158
NCT01794507Multiple Myeloma · United States, Australia, France1CompletedJul 16, 201966
NCT01794520Multiple Myeloma · United States, Belgium, France and more2CompletedNov 29, 2021117
NCT01686555Lupus Erythematosus · United States, Germany, Mexico and more1CompletedJun 201597
NCT01682616Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia1CompletedJun 23, 202249
NCT01594229Lymphoma, Non-Hodgkin · United States1CompletedJul 14, 202060
NCT01328626Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia1CompletedMay 8, 2020222

How it is read

Names in the registry

  • “Venetoclax”, 66 entries
  • “ABT-199”, 9 entries
  • “venetoclax”, 6 entries
  • “ABT-199 (Main Cohort)”, 1 entry
  • “ABT-199 (Safety Expansion Cohort)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.